These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580 [TBL] [Abstract][Full Text] [Related]
12. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852 [TBL] [Abstract][Full Text] [Related]
13. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224 [TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH Mult Scler; 2020 Nov; 26(13):1670-1681. PubMed ID: 31610732 [TBL] [Abstract][Full Text] [Related]
15. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M Eur J Neurol; 2023 May; 30(5):1389-1399. PubMed ID: 36779855 [TBL] [Abstract][Full Text] [Related]
16. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ; Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883 [TBL] [Abstract][Full Text] [Related]
17. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376 [TBL] [Abstract][Full Text] [Related]
18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
19. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients. Valentino P; Malucchi S; Bava CI; Martire S; Capobianco M; Malentacchi M; Sperli F; Oggero A; Di Sapio A; Bertolotto A Mult Scler Relat Disord; 2023 Sep; 77():104893. PubMed ID: 37481820 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis. Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]